(August 31, 2022) The United States Patent Trial and Appeal Board (PTAB) has rejected a challenge against Aker BioMarine’s patent US10,010,567B2 which protects capsules of high-quality krill oil comprising at least 35 percent phospholipids and low levels of free fatty acids.
In its decision published on May 18th, 2022, PTAB concluded that the patent has been upheld and validated on all accounts and all procedural options are exhausted, giving Aker BioMarine a strong patent covering sales of krill oil in the United States until March 2028.
This conclusion follows the European Patent Office Board of Appeal’s decision in 2021 related to the key European family member covering similar production and composition.
Strong Patent Portfolio in the U.S. Promises Continual Growth
Since inception, Aker BioMarine has been committed to scientific research and business development in the nutraceuticals market by both developing its own patented technology and by acquiring technology developed by others. As a result, Aker BioMarine has the world’s largest and most innovative patent portfolio in the krill industry. With the upheld patent in the U.S., the company is poised for continual growth and evolution, helping to bring new and novel concepts to consumers in the years to come.
This is further validation of Aker BioMarine’s contribution to the industry’s technology and our innovative capabilities. We will continue to develop our portfolio based on our research and development to provide our customers with a superior product and are very pleased that PTAB has recognized our efforts,” said Kristin Holmgren, intellectual property manager at Aker BioMarine.
“We have invested heavily into our sustainable harvesting method, value chain and product R&D for the past 16 years. Today, we hold a strong position as industry leader globally and are passionate about producing the best krill oil on the market. We will continue to invest in solid partnerships, as this is certainly a great asset for our customers”, said Simon Seward, EVP Human Health and Nutrition at Aker BioMarine.
About Aker BioMarine
Aker BioMarine is a biotech innovator and Antarctic krill-harvesting company, dedicated to improving human and planetary health. Listed on Oslo Stock Exchange, the company develops krill-based ingredients for pharmaceutical, nutraceutical (Superba®), aquaculture(QRILL®Aqua), and animal feed applications (QRILL®Pet), including INVI™, a highly concentrated protein isolate, and LYSOVETA™, a targeted transporter of EPA and DHA from krill. Aker BioMarine’s fully transparent value chain stretches from sustainable krill harvesting in pristine Antarctic waters through its Montevideo logistics hub, Houston production plant, and to customers around the world. The company’s strong focus on sustainability inspired the launch of AION by Aker BioMarine, a circularity company dedicated to helping companies to recycle and reuse waste. For further information, go to www.akerbiomarine.com.
For more information, please contact:
Marte Dalsegg
Communications Director,
marte.dalsegg@akerbiomarine.com
+47 934 33 087